Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | RXRG | P48443 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735695 | 1.00 | KEAP1 (0.41) | KEAP1NFE2L2KDM4ELMNAAKR1C3 | |
| SCHEMBL1138805 | 0.91 | KEAP1 (0.40) | KEAP1NFE2L2KDM4ELMNAAKR1C3 | |
| SCHEMBL12863735 | 0.91 | KEAP1 (0.40) | KEAP1NFE2L2KDM4ELMNAAKR1C3 | |
| SCHEMBL1139554 | 0.90 | KDM4E (0.42) | KEAP1NFE2L2KDM4ELMNAAKR1C3 | |
| SCHEMBL1139450 | 0.90 | KDM4E (0.42) | KEAP1NFE2L2KDM4ELMNAAKR1C3 | |
| SCHEMBL1139125 | 0.89 | RXRA (0.48) | KEAP1NFE2L2RXRARXRBRXRG | |
| SCHEMBL1139142 | 0.88 | AKR1C3 (0.43) | KDM4ELMNAAKR1C3 | |
| SCHEMBL12863537 | 0.88 | AKR1C3 (0.43) | KDM4ELMNAAKR1C3 | |
| SCHEMBL6863897 | 0.88 | KEAP1 (0.51) | KEAP1NFE2L2KDM4ELMNAAKR1C3 | |
| SCHEMBL6863901 | 0.88 | KEAP1 (0.51) | KEAP1NFE2L2KDM4ELMNAAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0947500-B1 | SULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-02-23 | — | — | EP | claimed |
| US-20080312326-A1 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | THE JOHN HOPKINS UNIVERSITY (US) | 2008-12-18 | — | — | US | claimed |
| WO-2006135545-A2 | A METHOD FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES CHARACTERIZED BY ADMINISTERING AN EP1 RECEPTOR ANTAGONIST | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-12-21 | — | — | WO | claimed |
| US-20040102524-A1 | Method of treatment | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | claimed |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1370266-A1 | METHOD OF TREATMENT | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | claimed |
| WO-2002072098-A1 | METHOD OF TREATMENT | ASTRAZENECA AB (SE) | 2002-09-19 | — | — | WO | claimed |
| US-6448290-B1 | PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-10 | — | — | US | claimed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | claimed |
| EP-0947500-B1 | SULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20080312326-A1 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | THE JOHN HOPKINS UNIVERSITY (US) | 2008-12-18 | — | — | US | disclosed |
| US-7335776-B2 | Remedies for depression containing EP1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-26 | — | — | US | disclosed |
| US-20070167500-A1 | Remedy for urinary tract diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| WO-2006135545-A2 | A METHOD FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES CHARACTERIZED BY ADMINISTERING AN EP1 RECEPTOR ANTAGONIST | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | disclosed |
| WO-2002072098-A1 | METHOD OF TREATMENT | ASTRAZENECA AB (SE) | 2002-09-19 | — | — | WO | disclosed |
| US-6448290-B1 | PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| WO-2000069465-A1 | ANTICANCER AGENTS CONTAINING EP1 ANTAGONISTS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-11-23 | — | — | WO | disclosed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312326-A1 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | PTGER1, PSEN1, EPN1 | KEAP1 332/4885NFE2L2 830/4885KDM4E 4351/4885 |
| US-20070167500-A1 | Remedy for urinary tract diseases | PTGER3, PTGER1, PTGES3 | KEAP1 502/4885NFE2L2 592/4885KDM4E 3619/4885 |
| US-20040102524-A1 | Method of treatment | PTGER1, PTGS1, PTGER2 | KEAP1 881/4885NFE2L2 1289/4885KDM4E 4015/4885 |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | PTGER1, PTGER2, PTGS1 | KEAP1 1880/4885NFE2L2 537/4885KDM4E 4138/4885 |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | CNR1, HCAR1, HCAR2 | KEAP1 2167/4885NFE2L2 726/4885KDM4E 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.